A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants
Clinical trial NCT05943977 · COMPLETED
Trial details
- NCT number
- NCT05943977
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-02
- Primary completion
- 2023-11-30
- Enrollment
- 121
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.